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Abstract
Background: Metastatic melanoma is an aggressive malignancy that is resistant to therapy and has a poor
prognosis. The progression of primary melanoma to metastatic disease is a multi-step process that requires
dynamic regulation of gene expression through currently uncharacterized epigenetic mechanisms. Epigenetic
regulation of gene expression often involves changes in chromatin structure that are catalyzed by chromatin
remodeling enzymes. Understanding the mechanisms involved in the regulation of gene expression during
metastasis is important for developing an effective strategy to treat metastatic melanoma. SWI/SNF enzymes are
multisubunit complexes that contain either BRG1 or BRM as the catalytic subunit. We previously demonstrated that
heterogeneous SWI/SNF complexes containing either BRG1 or BRM are epigenetic modulators that regulate
important aspects of the melanoma phenotype and are required for melanoma tumorigenicity in vitro.
Results: To characterize BRG1 expression during melanoma progression, we assayed expression of BRG1 in patient
derived normal skin and in melanoma specimen. BRG1 mRNA levels were significantly higher in stage IV
melanomas compared to stage III tumors and to normal skin. To determine the role of BRG1 in regulating the
expression of genes involved in melanoma metastasis, we expressed BRG1 in a melanoma cell line that lacks BRG1
expression and examined changes in extracellular matrix and adhesion molecule expression. We found that BRG1
modulated the expression of a subset of extracellular matrix remodeling enzymes and adhesion proteins.
Furthermore, BRG1 altered melanoma adhesion to different extracellular matrix components. Expression of BRG1 in
melanoma cells that lack BRG1 increased invasive ability while down-regulation of BRG1 inhibited invasive ability in
vitro. Activation of metalloproteinase (MMP) 2 expression greatly contributed to the BRG1 induced increase in
melanoma invasiveness. We found that BRG1 is recruited to the MMP2 promoter and directly activates expression
of this metastasis associated gene.
Conclusions: We provide evidence that BRG1 expression increases during melanoma progression. Our study has
identified BRG1 target genes that play an important role in melanoma metastasis and we show that BRG1
promotes melanoma invasive ability in vitro. These results suggest that increased BRG1 levels promote the
epigenetic changes in gene expression required for melanoma metastasis to proceed.
Background
Melanoma is an aggressive malignancy, characterized by
high potential for metastasis and notoriously resistant to
chemotherapeutics [1,2]. The prognosis for patients with
melanoma is dependent on the stage of the disease as
measured by tumor thickness, ulceration, and the pre-
sence of metastases [3]. According to the American
Joint Committee on Cancer staging system, Stage I mel-
anomas are less than 1 mm thick and localized to the
skin. Stage II melanomas are greater than 1 mm thick,
may be ulcerated, but are still localized to the skin. In
stage III, the tumor has spread to nearby lymph nodes
but not yet detected at distant sites. In stage IV, the
tumor has spread beyond the original area of skin and
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of the skin or lymph nodes. Thef i v ey e a rs u r v i v a lr a t e
for stage I, II, III, and IV is estimated to be 92%, 68%,
45%, and 11% respectively [4]. The high mortality rate
associated with metastatic melanoma and the lack of
effective treatment underscores the necessity to under-
stand the mechanisms that promote melanoma
progression.
The progression from a primary tumor to metastatic
melanoma is a multistep process that involves detach-
ment from the primary tumor mass, invasion into the
dermis, migration through the extracellular matrix
(ECM), and vasculature and colonization of distant sites
[5,6]. Each of these steps involves cytoskeletal alterations
as well as changes in the tumor cell’s interactions with
neighboring cells and with the ECM [7]. The inherently
high metastatic potential associated with melanoma has
been attributed to the migratory nature of neural crest
derived precursors that give rise to the melanocyte line-
age [8]. Metastatic potential is also dependent on pro-
metastatic genetic changes such as those involving
NEDD9 amplification as well as epigenetic changes that
modulate the expression of genes required for each step
in the process [9,10]. Thus, the propensity for mela-
noma to metastasize may be intrinsically determined,
permanently fixed by genetic alterations, and dynami-
cally modulated at an epigenetic level by signals from
the changing microenvironment.
Epigenetic regulation of gene expression often involves
changes in chromatin structure that are catalyzed by
chromatin remodeling enzymes [11,12]. Two classes of
enzymes remodel chromatin structure by catalyzing
covalent histone modifications or by hydrolyzing ATP
to mobilize nucleosomes [13]. SWI/SNF complexes are
ATP dependent chromatin remodeling enzymes that
have been shown to increase DNA accessibility, allowing
gene specific regulators or general transcription factors
to bind and to activate or repress gene expression [13].
SWI/SNF enzymes play critical roles during organism
development [14]. Particularly relevant to melanoma is
t h er e g u l a t o r yr o l et h a tS W I / S N Fe n z y m e sp l a yi np r o -
moting neural crest migration and differentiation as well
as SWI/SNF interactions with Microphthalmia -Asso-
ciated Transcription Factor (MITF), a lineage survival
oncogene in melanoma [15-17].
Mammalian SWI/SNF complexes are composed of the
BRG1 or BRM catalytic ATPase subunit and 9-12
BRG1/BRM associated factors (BAFs) [18]. Diverse
SWI/SNF complexes are distinguished by the particular
ATPase and the presence of unique BAFs [19]. The
BRG1 and BRM containing complexes have similar
chromatin remodeling activity in vitro but do not neces-
sarily have redundant functional roles in vivo [20].
Dependent on the cellular context, BRG1 and BRM play
overlapping or distinct roles in tumorigenesis. Both
BRG1 and BRM expression is down-regulated in lung
cancer [21]. However, low expression of BRM has been
associated with gastric cancer while high expression of
BRG1 has been associated with advanced stages of gas-
tric and prostate cancer [22-24].
Reconstitution of SWI/SNF subunits into cancer cells
that lack expression typically induces a change in mor-
phology [25,26]. Furthermore, disruption of SWI/SNF
activity by the introduction of dominant negative BRG1
and BRM into normal cells dramatically alters cell size
and shape and invasiveness [27]. These morphological
changes parallel changes in the expression of cytoskele-
tal regulators, cell surface proteins, adhesion molecules,
and enzymes that degrade the ECM [26-30]. Thus, SWI/
SNF enzymes play an important role in regulating the
expression of genes important for tumor metastasis. We
previously demonstrated that BRG1 and BRM expres-
sion is variable in melanoma cell lines, such that some
cell lines express elevated levels of BRG1 and BRM and
a subset of cell lines are deficient in BRG1 or BRM [31].
We found that reconstitution of BRG1 in a BRG1 defi-
cient melanoma cell line promoted expression of MITF
target genes that regulate melanogenesis and survival.
Furthermore, BRG1 promoted resistance to cisplatin
and down-regulation of BRG1/BRM significantly com-
promised tumorigenicity. An independent study deter-
mined that sequential down-regulation of BRG1 and
BRM inhibits melanoma proliferation [32]. These studies
suggest that SWI/SNF enzymes are important epigenetic
modulators of melanoma tumorigenicity and potentially
regulate metastatic potential.
To further characterize BRG1 expression in mela-
noma, we assayed expression of BRG1 in patient derived
metastatic melanomas. We found that BRG1 mRNA
levels were significantly higher in stage IV tumors com-
pared to stage III tumors and to normal skin. Further-
more, BRG1 protein levels were elevated in highly
invasive human metastatic melanoma cell lines. We
expressed BRG1 in an established melanoma cell line
that lacks detectable levels of BRG1 and profiled expres-
sion of extracellular matrix and adhesion molecules. We
f o u n dt h a tB R G 1m o d u l a t e dt h ee x p r e s s i o no fas u b s e t
of cell surface receptors, adhesion proteins, and extracel-
lular matrix remodeling enzymes. Furthermore, BRG1
altered adhesion to different ECM components and pro-
moted invasion through matrigel. Activation of matrix
metalloproteinase (MMP) 2 expression in BRG1 expres-
sing cells was determined to contribute to the BRG1
mediated increase in invasive ability. Down-regulation of
BRG1 in a highly invasive melanoma cell line resulted in
decreased MMP2 expression and decreased invasive
ability. We investigated the mechanisms involved in
BRG1 mediated activation of MMP2 expression and
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tor of MMP2, the SP1 transcription factor, and is
recruited to the matrix metalloproteinase (MMP) 2 pro-
moter. In combination, these results suggest that BRG1
plays a role in promoting melanoma progression by reg-
ulating the expression of metastasis associated genes.
Results
BRG1 is highly expressed in metastatic melanoma
To evaluate BRG1 expression during melanoma progres-
sion, we examined BRG1 mRNA levels using quantita-
tive (qPCR) arrays (Origene) containing normalized
cDNA prepared from patient derived normal skin (3
samples), from stage III (21 samples) and stage IV (19
samples) metastatic melanoma specimen. Although
BRG1 mRNA levels were lower in a subset of individual
melanoma samples compared to normal skin, the aver-
age level of BRG1 was higher in stage III (1.2 fold) and
stage IV melanoma (1.7 fold) compared to that in nor-
m a ls k i n( F i g u r e .1 A ) .T h eh i g h e rl e v e l so fB R G 1i n
stage IV melanoma compared to normal skin was statis-
tically significant (p < .05). There was also a statistically
significant increase in BRG1 mRNA levels in stage IV
melanoma compared to stage III melanoma (p < .01).
Although there was also a trend toward increased BRG1
expression in stage III melanoma compared to normal
skin, the increase was not statistically significant, possi-
bly due to an insufficient normal skin sample size. Inter-
estingly, microarray profiling of primary melanoma
tumors compared to normal skin revealed that BRG1
mRNA levels in primary melanoma is significantly
higher than in normal skin [33,34] (Additional file. 1).
In combination, these data suggest that BRG1 mRNA
levels are elevated in primary melanoma compared to
normal skin and increase during disease progression
(from stage III to IV).
We and others determined that SK-MEL5 cells, derived
from an axillary node melanoma, are deficient in BRG1
expression [31,32]. To determine whether BRG1 protein
levels are consistently down regulated in other metastatic
melanoma cell lines, we compared BRG1 protein levels in
SK-MEL5 cells with levels in two highly metastatic mela-
noma cell lines, A375SM and WM-266-4. The A375SM
cell line was established from a lung metastasis formed
by injection of parental cells into nude mice [35]. The
WM-266-4 cell line was derived from a lymph node
metastasis [36]. We found that both A375SM and WM-
266-4 express high levels of BRG1 compared to SK-
MEL5 cells and to normal human melanocytes (Figure.
1B). We previously reported that re-introduction of
BRG1 in SK-MEL5 cells promotes pigmentation as well
as increased resistance to cisplatin [31]. As shown in Fig-
ure. 1B, BRG1 reconstituted SK-MEL5 cells express
BRG1 at similar levels as A375SM and WM-266-4, which
we previously estimated to be approximately 2 fold
higher than that in normal melanocytes [31].
BRG1 modulates extracellular matrix and adhesion
molecule expression in SK-MEL5 melanoma cells
A previous microarray study showed that re-expression
of BRG1 in a BRG1/BRM deficient human adrenal ade-
nocarcinoma cell line (SW13 cells), activated the expres-
sion of 80 genes and repressed the expression of 2
genes [28]. Many of the BRG1 regulated genes were cell
surface proteins and extracellular matrix remodeling
enzymes or secreted proteins such as CD44, E-cadherin,
matrix metalloproteinase (MMP) 2, and osteonectin
(SPARC) [28-30]. Thus, re-expression of BRG1 in
BRG1/BRM deficient adenocarcinoma cells alters the
expression of a subset of genes, and in particular the
expression of genes that potentially have important roles
in regulating tumor metastasis.
To evaluate how re-expression of BRG1 in the BRG1
deficient melanoma cell line, SK-MEL5, alters the expres-
sion of metastasis associated gene expression, we exam-
ined BRG1 induced changes in gene expression using
quantitative RT
2 Profiler PCR Arrays (SABiosciences)
and assayed the expression of 84 genes related to cell-cell
and cell matrix interactions (Additional file 2). We found
that the expression of 13 genes on the array was highly
up-regulated by BRG1 (greater than 4-fold) (Figure. 2A).
The most highly up-regulated genes (greater than 10
fold) were neural cell adhesion molecule (NCAM1), E-
cadherin (CDH1), catenin delta 2/neural plakophilin
related armadillo protein (CTNND2), MMP2, and lami-
nin b3 (LAMB3) (Figure. 2A). Other highly activated
genes (greater than 4 fold) included MMP10, tissue spe-
cific inhibitor of metalloproteinase (TIMP) 3, integrins
a3 and a7, two collagen genes, and genes encoding com-
ponents of the basement membrane (Figure. 2A).
BRG1 activated the expression of 10 additional genes at
least two fold, including CD44, MMP9 and MMP14
(MT1-MMP) (greater than 2 fold) (Figure. 2B). Interest-
ingly, re-expression of BRG1 also significantly inhibited
the expression of 8 genes (Figure. 2C), while the remain-
ing 53 genes on the array were not significantly affected
by the expression of BRG1 (Additional file 1, Table 1).
Thus our data indicate that re-expression of BRG1 in
BRG1 deficient melanoma cells affects the expression of
a subset of cell surface and extracellular matrix remo-
deling enzymes, some of which overlap (E-cadherin,
CD44, and MMP2) and some which are distinct from
those reported to be modulated by reconstitution of
BRG1 in BRG1/BRM deficient SW13 adenocarcinoma
cells. Many of the genes we found to be modulated by
BRG1 (Figure. 2A, B, and 2C) encode proteins that play
a role in regulating melanoma invasiveness and meta-
static potential [6,7,37].
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SK-MEL5 cells was NCAM1 (Figure. 2A). NCAM1 is a
cell adhesion molecule (CAM) in the immunoglobulin
superfamily that is expressed at the cell surface and
mediates cell to cell and cell matrix interactions [38].
High expression of NCAM1 in malignant neoplasms,
including melanoma, is associated with an aggressive
tumor phenotype [39]. Although high levels of NCAM1
have been associated with metastatic potential, the func-
tional role of NCAM1 in melanoma has not been
demonstrated, and high levels of NCAM1 have also
been detected in benign nevi [40]. Thus, the role of
NCAM1 in melanoma metastasis is unclear. MCAM
(MUC18), a related cell adhesion molecule is over-
expressed in advanced primary and metastatic mela-
noma. Its expression in melanoma cell lines enhances
metastatic potential in nu d em i c e[ 4 1 , 4 2 ] .W ef o u n d
that in addition to NCAM1, BRG1 significantly
increased the expression of MCAM (Figure. 2D). Thus,
re-expression of BRG1 in SK-MEL5 cells activated the
Figure 1 BRG1 is highly expressed in patient derived melanomas and metastatic melanoma cell lines. A. Tissue Scan Melanoma qPCR
Arrays (Origene) containing cDNAs from patient derived normal skin, stage III melanomas, and stage IV melanomas were subjected to qRT-PCR
with BRG1 specific primers. BRG1 levels were normalized to b-actin. The results were averaged from values obtained by performing three PCR
arrays. B. Western blot comparing BRG1 levels in two invasive melanoma cell lines (A375SM and WM-266-4) and human epidermal melanocytes
with that in BRG1 deficient SK-MEL5 cells, SK-MEL5 cells reconstituted with empty vector (EV), and BRG1 reconstituted SK-MEL5 cells. Total cell
lysate was loaded. Tubulin is a loading control.
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have been implicated in promoting tumor metastasis.
We verified that the changes in NCAM1 and MCAM
expression also occurred at the protein level (Figure.
2E). Interestingly, increased levels of the 140KD
NCAM1 isoform was detected in BRG1 expressing cells.
This isoform is associated with malignant neoplasms
and induction of anti-apoptotic programs [39].
E-cadherin localization to the cell junction is
compromised in BRG1 reconstituted SK-MEL5 cells
Two of the most highly activated genes in BRG1 expres-
sing SK-MEL5 cells were E-cadherin (CDH1) and catenin
delta 2/neural plakophilin related armadillo protein
(CTNND2) (Figure. 2A). E-cadherin is a calcium depen-
dent transmembrane receptor that localizes to adherens
junctions and mediates cell-cell adhesion. In many cancer
types, loss of E-cadherin expression coincides with acqui-
sition of an invasive phenotype and development of
metastatic disease. In normal melanocytes, E-cadherin
mediates melanocyte-keratinocyte interactions and loss
of E-cadherin expression or a change in its cellular distri-
bution is associated with early phases of melanoma.
Furthermore, over-expression of E-cadherin in melanoma
cells reduces melanoma invasiveness [43]. Thus, expres-
sion of BRG1 in SK-MEL5 cells could potentially reduce
melanoma invasiveness through up-regulation of E-cad-
herin. Interestingly, BRG1 also promoted expression of δ-
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Figure 2 BRG1 modulates the expression of extracellular matrix and adhesion molecule expression in SK-MEL5 cells. The expression of
extracellular and adhesion molecule related genes was profiled in control SK-MEL5 (empty vector) and BRG1 reconstituted SK-MEL5 cells using a
focused qPCR array. The expression level of each gene was normalized to a control value obtained by averaging the expression of four
housekeeping genes. The average of three to four independent experiments is shown. All changes in gene expression are statistically significant
as determined by the student’s t test (p value equal to or less than 0.05). A. Expression of genes that are activated greater than four-fold by
BRG1. B. Expression of genes that are activated greater than two fold by BRG1. C. Expression of genes that are down-regulated by BRG1. D.
MCAM expression was evaluated separately from the qPCR array using gene specific primers. Normalization of mRNA levels was to GAPDH. E.
Detection of NCAM1 and MCAM protein expression by Western blotting. Tubulin is a loading control.
Saladi et al. Molecular Cancer 2010, 9:280
http://www.molecular-cancer.com/content/9/1/280
Page 5 of 17catenin/neural plakophilin-related armadillo protein
(CTNND2) (Figure. 2A), but had no effect on the expres-
sion of b-catenin or a-catenin (data not shown), two
other members of armadillo/b-catenin superfamily of cell
adhesion molecules. Increased expression of CTNND2 in
prostate cancer has been associated with redistribution
and loss of E-cadherin at the adherens junction [44].
We verified that reconstitution of BRG1 in SK-MEL5
cells resulted in increased E-cadherin and CTNND2
expression at the protein level (Figure. 3A). To deter-
mine the status of E-cadherin at the cell surface in con-
trol SK-MEL5 cells and SK-MEL5 cells expressing
BRG1, we performed flow cytometry. We found that
although total E-cadherin expression increased (Figure.
3A), the localization of E-cadherin to the cell surface
was reduced in cells expressing BRG1 compared to con-
trol cells (Figure. 3B). Furthermore, immunofluorescence
revealed that E-cadherin was mostly cytoplasmic in
BRG1 expressing SK-MEL5 cells (Figure. 3C). Reduced
localization of E-cadherin to the cell surface suggested
that in SK-MEL5 cells, re-expression of BRG1 may
further compromise E-cadherin function.
BRG1 alters melanoma adhesion to different ECM
components
Re-expression of BRG1 in SK-MEL5 cells resulted in an
altered pattern of integrin expression (Figures. 2A and
2C). Integrins are transmembrane glycoproteins that
mediate specific interactions between cells and the ECM
and regulate migration [45]. Hetero-dimers composed of
a and b subunits serve as receptors with specificity for
different ligands. Integrin expression is a key determi-
nant of a cell’s ability to attach to different ECM com-
ponents and to migrate on these substrates. Aberrant
Figure 3 BRG1 promotes E-cadherin expression but compromises E-cadherin localization to the cell junction in SK-MEL5 cells.A .
Detection of E-cadherin (CDH1) and CTNND2 protein expression by Western blotting. Tubulin is a loading control. B. Cells were stained with
control IgG or an antibody to E-cadherin and FITC labeled secondary antibody. E-cadherin at the cell surface was quantified by FACS analysis.
Significantly less E-cadherin was localized to the cell surface in SK-MEL5 +BRG1 cells compared to control SK-MEL5 cells (p < 0.05). C. E-cadherin
staining of representative control SK-MEL5 cells and BRG1 expressing SK-MEL5 cells by immunofluorescence.
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progression [45].
BRG1 enhanced the expression of integrins a7 and a3
and inhibited the expression of integrins a4 and b3 (Fig-
ures. 2A and 2C). Modulation of integrin expression by
BRG1 suggested that reconstitution of BRG1 in BRG1
deficient melanoma cells might alter melanoma cell
interactions with specific ECM components. We com-
pared the ability of the control (empty vector) SK-MEL5
cells with that of the SK-MEL5 cells expressing BRG1 to
adhere to laminin, collagen, and fibronectin. We found
that BRG1 expressing cells demonstrated increased
adhesion to laminin and collagen and decreased adhe-
sion to fibronectin (Figure. 4). The observed increase in
adhesion to laminin is consistent with increased expres-
sion of integrin a7, which is a component of a7b1, a
complex that has high affinity for laminin [46].
Increased adhesion to collagen is consistent with
increased expression of a3, which is a component of the
a3b1 complex that has high affinity for several ECM
components, including collagen [45]. Reduced adhesion
to fibronectin is consistent with decreased expression of
a4, which forms the a4b1 complex and b3 which forms
the aVb3 complex, two integrins with high affinity for
fibronectin [45]. The expression of these integrins is ele-
vated in primary or metastatic melanomas [47-50], how-
ever it is not possible to designate specific integrins as
“pro-neoplastic” because their effect on tumor progres-
sion is dependent on the cellular context and the speci-
fic step in tumor progression [51]. Our data indicate
that BRG1 may regulate metastatic potential by modu-
lating the integrin profile and altering adhesiveness to
different ECM components.
MMP2 activity is up-regulated in BRG1 expressing SK-
MEL5 cells and contributes to increased melanoma
invasiveness
In addition to changes in adhesion, metastasis also
requires extensive ECM remodeling. The matrix metal-
loproteinases (MMPs) are the main proteases that remo-
del the ECM [52]. Re-expression of BRG1 in SK-MEL5
cells resulted in a dramatic increase in MMP2 and
MMP10 expression and a smaller but significant
increase in MMP9 and MMP14 (MT-MMP1) expression
(Figures. 2A and 2B) and a decrease in MMP1 and
MMP16 expression (Figure. 2C). We verified that the
observed changes in the mRNA profile resulted in con-
sistent changes in protein expression for MMP1,
MMP2, MMP9, and MMP14 (Figure. 5A).
Expression of MMPs is controlled at the transcrip-
tional and post-translational levels [53]. Our data indi-
cated that BRG1 promotes expression of MMP2,
MMP9, and MMP14 at the protein level (Figure. 5A).
MMP2 (gelatinase A, 72-kDa type IV collagenase) and
M M P 9( g e l a t i n a s eB ,9 2 - k D at y p eI Vc o l l a g e n a s ea r e
secreted as inactive pro-zymogens that are subsequently
processed and activated. MMP14 (MT1-MMP) is a
membrane bound MMP that activates MMP2 at the cell
surface [54]. Furthermore, naturally occurring tissue
inhibitor of metalloproteinases (TIMPs) down-regulate
MMP activity [55]. The balance between TIMP and
MMP expression is critically important in determining
overall MMP activity. We found that in addition to
MMPs, BRG1 also activated expression of TIMP2 and
TIMP3, which would be expected to down-modulate
MMP activity (Figures. 2A, 2B, and 5A).
In order to determine if re-expression of BRG1 in SK-
MEL5 cells resulted in increased secretion of active
MMP2 and MMP9, we performed gelatin zymography
on supernatants derived from control and BRG1 expres-
sing SK-MEL5 cells. We determined that although
TIMP levels were increased, there was still a substantial
increase in active MMP2 and MMP9 secreted by SK-
MEL5 cells expressing BRG1 compared to BRG1 defi-
cient SK-MEL5 cells (Figure. 5B).
The observed increase in MMP2 and MMP9 activity
as well as other alterations in extracellular matrix and
adhesion molecule expression suggested that BRG1
plays an important role in regulating melanoma inva-
siveness. To determine the overall biological conse-
quence of BRG1 re-expression in SK-MEL5 cells, we
investigated whether BRG1 promotes changes in the
ability of melanoma cells to be invasive in vitro. We
found that SK-MEL5 cells that express BRG1 had signif-
icantly increased ability to invade through Matrigel
coated Boyden chambers (Figure. 5C).
To elucidate the mechanisms by which BRG1 pro-
motes invasion, we treated cells with an inhibitor of
MMP2/MMP9 and performed invasion assays. We
found that inhibition of MMP2 and MMP9 activity par-
tially abrogated the BRG1 mediated increase in invasive
ability (Figure. 5D). Consistently, siRNA mediated
down-regulation of MMP2 (Figure. 5E) also reduced the
BRG1 medicated increase in invasiveness (Figure. 5F).
Thus, activation of MMP2 and possibly MMP9 expres-
sion contributes to the BRG1 induced increase in SK-
MEL5 invasive ability.
Down-regulation of BRG1 in WM-266-4 cells inhibits
melanoma invasiveness
Most established melanoma cell lines express high levels
of BRG1 [31], including two metastatic melanoma cell
lines, A375SM and WM-266-4 (Figure. 1B). This raised
the possibility that BRG1 is required for these cells to
be invasive. To determine if loss of BRG1 compromises
invasive ability in one of these highly invasive cell lines,
we down-regulated BRG1 expression in WM-266-4 cells
using a pool of siRNAs that target BRG1 but not the
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formed a timecourse after siRNA transfection and deter-
mined that BRG1 down-regulation was effective 120
hours after transfection (Figure. 6B). Interestingly, BRM
expression was slightly lower in cells transfected with
control siRNA compared to untreated but then
increased in BRG1 down-regulated cells. However,
expression of the BRG1/BRM associated factor, INI1,
did not change as a result of siRNA transfection. Pre-
vious studies have suggested that BRM expression is
highly sensitive to growth conditions [56]. We found
that in WM-266-4 cells, BRM expression but not BRG1
or INI1 expression is sensitive to changes in WM-266-2
confluency (Additional file 3). Thus, we speculate that
siRNA transfection may have an inhibitory effect on
BRM expression because of non-specific effects on pro-
liferation. Nevertheless, BRM expression was elevated in
BRG1 knockdown cells compared to both untreated
cells and cells that expressed control siRNA (Figure. 6B).
We found that down-regulation of BRG1 resulted in
decreased MMP2 and MCAM expression (Figure. 6C)
and reduced invasion through Matrigel-coated Boyden
Figure 4 BRG1 expression alters adhesion of SK-MEL5 cells to different ECM components.9 6w e l lp l a t e sw e r ec o a t e dw i t hl a m i n i n ,
collagen, or fibronectin and blocked with BSA. Control SK-MEL5 cells expressing empty vector (EV) and SK-MEL5 cells expressing BRG1 were
seeded onto coated plates at a density of 2 × 10
4 cells. After incubation for 30 minutes, plates were washed and the cells stained with crystal
violet. Control plates coated with BSA were also included but did not retain cells after washing (data not shown). Representative fields are
shown (20× magnification). Adhesion was quantified by reading absorbance at 550 nm. The data shown is the average of two independent
experiments done in triplicate. The fold change in adhesion to all three substrates was significantly altered by expression of BRG1 (p < 0.01). A.
Adhesion to laminin. B. Adhesion to collagen. C. Adhesion to fibronectin.
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Page 8 of 17chambers (Figure. 6D). Furthermore, although BRM
levels increased in BRG1 down-regulated cells, our data
suggest that BRM can not compensate for these BRG1
specific functions. Thus, both a gain of function and
loss of function approach show that high levels of BRG1
promote melanoma invasive ability in vitro.
SP1 interacts with BRG1 to regulate MMP2 expression in
SK-MEL5 cells
Our data suggested that activation of MMP2 is an
important mechanism by which BRG1 promotes mela-
noma cell invasive ability. To determine the mechanism
by which BRG1 activates MMP2 expression in SK-
MEL5 melanoma cells, we investigated whether BRG1
intereacts with a transcriptional regulator of MMP2.
BRG1 was previously shown to directly activate the
MMP2 promoter through interactions with the tran-
scription factor, SP1 in SW13 cells [30]. Similarly, we
found that siRNA knockdown of SP1 (Figure. 7A)
reduced the level of MMP2 that was secreted by SK-
MEL5+BRG1 cells (Figure. 7B). Furthermore, we
detected a physical interaction between BRG1 and SP1
(Figure. 7C) and found that BRG1 was recruited to the
MMP2 promoter (Figure. 7D). As was previously
demonstrated in SW13 cells, BRG1 significantly
increased the binding of SP1 to the MMP2 promoter
Figure 5 MMP2 activity is up-regulated in BRG1 expressing SK-MEL5 cells and promotes invasion through matrigel. A. Detection of
MMP and TIMP protein expression by Western blotting. Tubulin is a loading control. B. MMP activity in control (EV) and SK-MEL5 expressing
BRG1 was determined by zymography. Cells were cultured in serum free media for 24 hours and the supernatant collected and normalized to
cell number. C. Invasion assays were performed using matrigel coated chambers with 5% FBS as a chemoattractant. Control SK-MEL5 cells (EV)
and SK-MEL5 cells expressing BRG1 were seeded at a density of 1.25 × 10
5 cells per well on top of control or matrigel inserts. Percent invasion
through matrigel was calculated relative to migration through the control insert. The data shown is the average of two independent
experiments done in triplicate. Expression of BRG1 significantly increased invasion (p < 0.01). D. Vehicle treated (DMSO) or BiPS (10μM) treated
BRG1 expressing SK-MEL5 cells were subjected to the invasion assay as described in C. The data shown is representative of two independent
experiments performed in duplicate. Treatment with the MMP2/MMP9 inhibitor, BiPS significantly inhibited invasion (p < 0.01). E. SK-MEL5 +BRG1
cells were transfected with Acell SMART Pool siRNAs targeting MMP2 or red non-targeting siRNAs and analyzed by Western blotting 120 hours
after transfection. F. Control and MMP2 down-regulated SK-MEL5+BRG1 cells were subjected to the invasion assay as described in C, 120 hours
after transfection with siRNAs. Invasion assays were performed in triplicate. Down-regulation of MMP2 significantly compromised invasion (p <
0.01).
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Page 9 of 17[57] (Figure. 7E). This data suggests that BRG1 directly
regulates MMP2 expression in melanoma cells through
interactions with SP1 and by facilitating SP1 association
with the MMP2 promoter. Interestingly, SP1 has been
shown to preferentially interact with the BRG1 catalytic
subunit in vitro [57]. Thus, a specific role for BRG1 in
the activation of MMP2 and melanoma invasiveness
may result from selective interactions with the SP1 tran-
scriptional regulator.
Discussion
Melanoma progression is a dynamic process that
requires tumor cells to possess decreased adhesive inter-
actions with surrounding cells and with the extracellular
matrix at some points in the metastatic cascade and
increased adhesive interactions at other times [58].
Metastatic potential also depends on adequate vasculari-
zation and the ability to degrade components of the
ECM. These processes are regulated by reversible
changes in the expression of genes involved in cell
attachment, motility, and proteolytic degradation of the
ECM [59]. Previous studies showed that SWI/SNF
enzymes modulate expression of ECM related molecules
in normal and cancer cells [27-30]. Furthermore, altera-
tions in the expression of SWI/SNF components have
been implicated in oncogenesis and multiple subunits
have been determined to play tumor suppressive roles
[60]. We previously characterized SWI/SNF subunit
Figure 6 Down-regulation of BRG1 inhibits melanoma invasion through matrigel. A. WM-266-4 melanoma cells transfected with control
(DY-547 labeled) siRNAs were visualized by phase-contrast microscopy. B. WM-266-4 melanoma cells were transfected with Acell SMART Pool
siRNAs targeting BRG1 or red non-targeting siRNAs and analyzed by Western blotting. C. Control and BRG1 down-regulated WM-266-4 cells were
subjected to the invasion assay as described in Figure. 5, 120 hours after transfection with siRNAs. Invasion was significantly compromised in
BRG1 down-regulated cells (p < 0.01).
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set of melanoma cell lines was depleted in either the
BRG1 or BRM catalytic subunit. Restoration of BRG1 in
a melanoma cell line that lacks BRG1 expression
enhanced the expression of MITF target genes and pro-
moted increased resistance to cisplatin [31].
To further characterize BRG1 expression in mela-
noma, we assayed expression in melanoma tumors. In
the present study, we determined that BRG1 mRNA
levels are significantly up-regulated in stage IV mela-
noma tumors when compared to normal skin or stage
III melanoma tumors. Furthermore, primary melanoma
tumors and most melanoma cell lines express high
levels of BRG1 (Figure. 1B, Additional file 1) [31,32]. A
recent study indicated that BRG1 expression is increased
at the protein levels in primary melanoma tumors com-
pared to dysplastic nevi, but that there is no significant
difference in BRG1 levels between primary and meta-
static melanoma samples [61]. However, this study
found that there may be a tendency for negative to
weak BRG1 expression to be associated with a better
patient survival [61]. In contrast, a separate study sug-
gested that BRG1 protein expression is frequently
down-regulated in primary and metastatic melanoma
compared to normal skin, but that a higher proportion
of metastatic melanoma tumors express BRG1 com-
pared to primary tumors [62]. These studies in combi-
nation with our present study suggest that BRG1 status
plays a role in melanoma progression, however further
investigations that utilize larger sample sizes will be
required to resolve the discrepancies between the differ-
ent studies.
Re-expression of BRG1 in the BRG1/BRM deficient
human adrenal adenocarcinoma cell line, SW13 prefer-
entially alters the expression of a limited number of
genes that mostly encode cell surface and ECM interact-
ing proteins [28]. Re-introduction of BRG1 in a BRG1
deficient breast cancer cell line, ALAB also had a high
Figure 7 SP1 interacts with BRG1 to regulate MMP2 expression. A. SK-MEL5 +BRG1 cells were transfected with Acell SMART Pool siRNAs
targeting SP1 or red non-targeting siRNAs. SP1 expression was analyzed by Western blotting 144 hours after transfection. B. MMP2 secretion in
control and SP1 down-regulated cells was analyzed by zymography 144 hours after transfection. C. Co-immunoprecipitations were performed
with FLAG antibody or control IgG. Co-immunoprecipitating proteins were analyzed by Western blotting with the indicated antibodies. D.
Chromatin immunoprecipitations (ChIPs) were performed with antibodies to SP1, BRG1, or control IgG and analyzed by qPCR with primers
specific for the MMP2 promoter or a control CD25 region. The results from two independent experiments were assayed twice. BRG1 was
significantly enriched on the MMP2 promoter compared to the control CD25 region (p < 0.01). SP1 binding to the MMP2 promoter was
significantly increased in SK+MEL5+BRG1 compared to control cells (p < 0.01).
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face and ECM interacting proteins [63]. This observa-
tion and the correlation between high BRG1 levels and
melanoma progression prompted us to study the impact
of BRG1 on the expression of genes involved in adhe-
sion and extracellular matrix remodeling in melanoma
cells.
Our study indicates that BRG1 activates the expres-
sion of both overlapping and distinct ECM related genes
in melanoma cells as those in SW13 cells (Figure. 8).
Expression of BRG1 in SK-MEL5 melanoma cells
resulted in the activation of MMP2, E-cadherin, and
CD44 as was also seen when BRG1 was expressed in
BRG1/BRM deficient SW13 cells [28-30]. However, the
expression of osteonectin (SPARC), a BRG1 dependent
gene in SW13 cells, was not significantly affected by re-
expression of BRG1 in SK-MEL5 cells [28] (Figure. 8,
Additional File 2). Furthermore, BRG1 activated and
repressed a number of cell surface and ECM interacting
genes in SK-MEL5 cells that have not been identified as
being BRG1 dependent in SW13 cells. Interestingly,
BRG1 had opposite effects on MMP1 expression in SK-
MEL5 cells compared to SW13 cells (Figure. 8) Thus,
the requirement for BRG1 in the activation of specific
genes is to a large extent cell context dependent. Inter-
estingly, we found that BRG1 activated the expression of
neural cell adhesion molecule (NCAM1) and δ-catenin/
neural plakophilin-related armadillo protein (CTNND2),
two genes whose expression is highly enriched in neural
cells. Activation of these neural specific genes by BRG1
may reflect the neural crest derivation of melanoma
cells.
Expression of BRG1 in melanoma cells modulated the
expression of a number of ECM related genes that have
opposing effects on melanoma invasiveness. In particu-
lar, BRG1 activated E-cadherin expression and down-
regulated the expression of MMP1 and integrins a4a n d
b3. Down-regulation of E-cadherin and high levels of
MMP1 and integrin aVb3 are associated with transition
from the radial non-invasive to the invasive vertical
growth phase and the acquisition of metastatic potential
in melanoma [37,64,65]. However, we found that BRG1
activated expression of other MMPs and integrins as
well as MCAM, all of which have been shown to be
important for promoting melanoma invasive ability and
tumor progression [37]. Melanoma cells employ distinct
strategies for invasion, each of which may differ in the
degree of dependence on the different molecular regula-
tors [6]. Interestingly, a previous study showed that
dominant negative BRG1 activates integrin aVe x p r e s -
sion but still inhibits the invasive ability of fibroblasts
[27]. In our studies, both a gain of function and loss of
function approach indicated that BRG1 promotes mela-
noma invasive ability, suggesting that high levels of
BRG1 promote mechanisms by which melanoma cells
invade that do not rely on the induction of all known
cell surface regulators.
The activation of MMP2 expression by BRG1 contrib-
uted to the increased invasive ability of BRG1 expressing
SK-MEL5 cells (Figures. 5C and 5D). BRG1 was pre-
viously shown to regulate MMP2 expression in SW13
cells by a transcriptional mechanism that involves SP1
[30]. Our data indicate that BRG1 activates MMP2
expression in melanoma cells by a similar mechanism
involving co-activation of SP1 mediated transcription
(Figure. 7). However, BRG1 inhibited the expression of
integrin b3, which is also regulated by SP1 [66]. The dif-
ferential requirement for SWI/SNF function in the regu-
lation of a transcription factor’s targets has been
previously observed and is not well understood [17,67].
A recent study suggests that diverse SWI/SNF com-
plexes and sub-complexes can be recruited to different
promoters and that the functional outcome of SWI/SNF
activity on specific promoters may be determined by the
composition of the SWI/SNF complex and the chroma-
tin context [68]. Furthermore, the recent observation
that SWI/SNF enzymes also regulate microRNA expres-
sion adds an additional layer of complexity to the overall
impact made by SWI/SNF enzymes in the regulation of
cellular gene expression profiles [69]. Further work will
be required to decipher the mechanisms by which a
high level of BRG1 results in a gene expression profile
that promotes melanoma invasiveness and potentially
dictates metastatic potential in vivo.
Figure 8 Comparison of extracellular matrix and adhesion
molecule regulation by BRG1 in SW13 and SK-MEL5 cells. Venn
diagram showing genes up-regulated by BRG1 in SW13 cells
(yellow), genes up-regulated by BRG1 in SK-MEL5 cells (red), and
genes down-regulated by BRG1 in SK-MEL5 cells (green). Three
genes were activated by BRG1 in both SWI3 and SK-MEL5 cells
(orange). Only genes that were assayed in both SK-MEL5 cells
(present study) and SW13 cells [28,29,76] are shown.
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nits, including BRG1, as tumor suppressors. Mutations
or down-regulation of BRG1 expression occurs in multi-
ple human tumors and haploinsufficiency of BRG1 pre-
disposes mice to mammary tumors [70]. Furthermore,
when re-expressed in SW13 cells, BRG1 interacts with
the retinoblastoma protein (Rb) to induce a G1 cell
cycle arrest [25]. These studies have implicated BRG1 as
a tumor suppressor that curbs proliferation. In contrast,
our data suggest that BRG1 expression is elevated in
melanoma and promotes melanoma invasiveness. Inter-
estingly, higher levels of BRG1 have also been associated
with prostate and gastric cancer invasiveness and tumor
progression [23,24]. A recent study showing that resi-
dual BRG1 expression is required for tumorigenesis to
occur in INI1 deficient mice suggests that the role of
BRG1 in tumorigenesis is more complex than previously
thought and that the outcome of BRG1 disruption may
be lineage specific [71]. We previously reported that
BRG1 interacts with MITF, the master regulator of mel-
anocyte differentiation and lineage addiction oncogene
in melanoma [31]. In this study, we found that BRG1
promotes expression of NCAM1 and CTNND2, two
markers that are highly expressed in neural crest derived
cells. Thus, the contrasting role of BRG1 in melanoma
may in part result from the lineage specific derivation of
this cancer type.
Conclusions
Our study suggests that over-expression of BRG1 contri-
butes to melanoma progression. We have determined
that BRG1 mRNA levels are higher in stage IV metastatic
melanomas compared to stage III melanomas and to nor-
mal skin. Furthermore, we have determined that BRG1
modulates the expression of extracellular matrix and
adhesion molecules that play an important role in mela-
noma metastasis. Our data indicate that modulation of
extracellular matrix and adhesion molecule expression by
BRG1 is associated with increased melanoma invasive
ability in vitro. The down-regulation of SWI/SNF compo-
nents in tumorigenesis has been elegantly demonstrated
in numerous studies and is further supported by mouse
models [60]. Our work adds to several other studies
[23,24,72] that suggest the over-expression of a SWI/SNF
component may also contribute to tumorigenesis.
Methods
Cell Culture
SK-MEL5 and WM-2664 melanoma cells were from the
ATCC. A375SM melanoma cells were a kind gift from
Dr. Menashe Bar-Eli (M.D. Anderson Cancer Center).
SK-MEL5 cells expressing an empty vector or BRG1
were described in [31]. Human melanocytes were from
Cascade Biologics (Portland, Oregon, USA) or Yale Cell
Culture Core Facility (New Haven, Connecticut, USA).
With the exception of melanocytes, all cells were grown
in DMEM supplemented with 10% FBS. Human mela-
nocytes were grown in Media 254 with added growth
supplements (Cascade Biologics). The MMP2/MMP9
inhibitor, 4-Biphenylylsulfonyl)amino-N-hydroxy-3-phe-
nylpropionamide (BiPS) was from Calbiochem (San
Diego, CA, USA) and was used at 10 μM.
RNA Isolation and Quantitative Real-time PCR
Total RNA was isolated with the Qiagen RNeasy mini
kit and reverse transcribed as described [31]. Quantita-
tive real-time PCR was performed in SYBR Green Mas-
ter Mix (Qiagen, Germantown, Maryland) with an
Applied Biosystems Prism 7500 PCR system and ana-
lyzed with the SDS software as described [31]. MCAM
and GAPDH primers were purchased from SABios-
ciences (Frederick, MD, USA).
Tumor qPCR Arrays
The Tissue Scan Melanoma qPCR Arrays (MERT501)
containing cDNAs from normal skin, stage III, and stage
IV melanomas were obtained from Origene Technolo-
gies (Rockville, MD, USA). The primers used to detect
BRG1 (SMARCA4) were from SABiosciences (Frederick,
MD, USA). BRG1 levels were normalized by amplifying
with primers to Human b-actin (Forward: CAGCCATG-
TACGTTGCTATCCAGG) and (Reverse: AGGTCCA-
GACGCAGGATGGCATG). The results were averaged
from values obtained by running three PCR arrays. Sta-
tistical significance was determined by utilizing a Mann-
Whitney Wilcoxon test.
Extracellular Matrix and Adhesion focused qPCR Arrays
Extracellular Matrix and Adhesion molecule RT
2 Profi-
ler PCR Arrays were purchased from SABiosciences
(Fedrick, MD). The primer sets in this array are
described in http://www.sabiosciences.com/rt_pcr_pro-
duct/HTML/PAHS-013A.html. CT values obtained for
84 extracellular matrix and adhesion molecule gene
expression were normalized to a value obtained by aver-
aging the CT values of four different housekeeping
genes. For each primer set, the fold change in SK-MEL5
+BRG1 cells was determined relative to values obtained
in control SK-MEL5 cells +empty vector. Average values
were obtained from four PCR arrays with cDNA from
control cells (from three different samples) and an addi-
tional four PCR arrays with cDNA from SK-MEL5 cells
+BRG1 (from three different samples). Statistical signifi-
cance was calculated using the student’s t test.
Antibodies
The Tubulin antibody was from Sigma (St. Louis, Mis-
souri, USA). FLAG M2 antibody and FLAG M2-Agarose
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MCAM antibodies were from BD Biosciences (San Jose,
C A ,U S A ) ,T h eB R G 1 ,N C A M 1a n dS P 1a n t i b o d i e s
were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The MMP2 and MMP9 antibodies were from
Cell Signaling (Beverly, MA, USA). The MMP14 anti-
body was from Millipore (Temecula, CA, USA). The
TIMP3 antibody was from Abcam (Cambridge, MA,
USA). Control IgG antibody used for ChIPs was from
Millipore (Billerica, MA, USA).
Cell extracts and immunoblot analysis
Cells were lysed in 20mMTris (pH 7.4),150 mM NaCl, 2
mM EDTA, 1% Triton X, 10% glycerol, supplemented
with a protease inhibitor cocktail (Sigma). SDS-PAGE
and Western blotting were carried out as described [73].
Flow Cytometry
Cells were incubated in fetal bovine calf serum (Invitro-
gen, Carlsbad, CA, USA) for 10 minutes at room tem-
perature to block nonspecific antibody binding and then
with the primary antibody or an isotype matched IgG
control for 20 minutes at 4°C. After one wash with
FACS buffer (PBS+0.5%BSA, 5% fetal calf serum, 0.1%
sodium azide, cells were incubated with secondary anti-
body for 20 minutes at 4°C, then washed twice with
FACs buffer. Cells were re-suspended in 0.1% parafor-
maldehyde then loaded onto a FACS-Calibur (BD Bios-
ciences, San Jose, CA, USA). Data was analyzed using
Cell Quest Pro (BD Biosciences). Statistical significance
was calculated using the student’s t test.
Immunocytochemistry
Immunocytochemistry was performed as described [17]
using an E-cadherin antibody (BD Biosciences) and goat
anti-mouse-Alexa Fluor568 (Molecular Probes). Images
were taken with a Nikon Eclipse TE2000-U fluorescence
microscope at 60× magnification.
Zymography
Zymography was performed as previously described [30].
Control SK-MEL5 and SK-MEL5+BRG1 cells were cul-
tured in serum free medium for 36 hours. Conditioned
medium was collected, normalized to cell number, and
subjected to electrophoresis in a polyacrylamide gel con-
taining 1 mg/ml gelatin. After electrophoresis, the gel
was washed in 2.5% Triton X-100 for 1 hour at room
temperature to remove the SDS and then incubated for
24 hours at 37°C in a buffer consisting of 5 mM CaCl2
and 1 μMZ n C l 2. The gel was stained in 0.25% Cooma-
sie Blue for 30 minutes, de-stained in methanol/acetic
acid solution and photographed on a light box. Proteoly-
tic activity was detected as white bands against a blue
background.
siRNA Knockdowns
Acell SMART Pool siRNAs targeting BRG1 (E-010431),
MMP2 (E-005959), SP1 (E-026959), and red non-target-
ing siRNAs (D-001960) were purchased from Dharma-
con Inc. (Chicago, Il., USA) and used to transfect
melanoma cells according to the manufacturer’s instruc-
tions. WM-266-4 cells were transfected with control or
siRNA targeting BRG1. BRG1 expressing SK-MEL5 cells
were transfected with control or siRNA targeting MMP2
or SP1.
Adhesion Assays
Adhesion assays were performed as previously described
[74]. 96 well plates were coated with laminin (10 ug/ml),
collagen (type 1) (20 ugm/ml), or fibronectin (20 ugm/
ml), and incubated at 4°C overnight. The plates are then
washed with Wash buffer (DMEM with 0.1% BSA) and
blocked in DMEM with 0.5% BSA for 45-60 minutes at
37°C. 2 × 10
4 cells were added to each well and incu-
bated at 37°C for 30 minutes. Non-adherent cells were
removed by washing three times with Wash buffer. The
cells are then fixed with paraformaldehyde and incu-
bated for 10-15 minutes and washed once with Wash
buffer. The cells were stained with crystal violet for 10
minutes, washed with water, and dried. 2% SDS was
added and the plates were incubated at room tempera-
ture for 30 minutes. Absorbance was read at 550 nm.
Statistical significance was calculated using the student’s
t test.
Matrigel Invasion Assay
Invasion assays were performed using matrigel coated
chambers (BD Biosciences, Bedford, MA, USA) as
recommended by the manufacturer. SK-MEL5 cells
expressing an empty vector or BRG1 were seeded in
serum free media at a density of 1.25 × 10
5 cells per
well on top of control or matrigel inserts. Media con-
taining 5% FBS was used as a chemoattractant. After
incubation for 16 hours, non-invading cells were
removed from the upper surface and invading cells were
stained with 1% Toluidine Blue and counted. Multiple
fields were counted in triplicate membranes with a
microscope at 20× magnification. The data shown is
from two independent experiments done in triplicate.
For studies involving inhibition of MMP2/MMP9, cells
were pre-treated with10 μM 4-Biphenylylsulfonyl)
amino-N-hydroxy-3-phenylpropionamide (BiPS) (Calbio-
chem, San Diego, CA, USA) for 3 hours and then plated
onto the Boyden chambers in media containing 10 μM
BiPS. For knockdown studies, invasion assays were per-
formed 120 hours after transfection of control or siR-
NAs targeting BRG1. Statistical significance was
calculated using a student’s t test.
Co-Immunoprecipitations
Co-immunoprecipitations were performed as previously
described [31].
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Chromatin Immunoprecipitations were performed as
previously described [31] using FLAG to detect FLAG-
BRG1 or IgG as a control. The primers used to detect
the MMP2 promoter were (Forward: GGGGAAAA-
GAGGTGGAGAAA) and (Reverse: CGCCTGAG-
GAAGTCTGGAT). CD25 primers were previously
described [75]. Statistical significance was calculated
using the student’s t test.
Additional material
Additional File 1: Gene expression profiling of BRG1 (SMARCA4).
The box plot is from a gene expression data set (Talantov, Clinical Cancer
Research, 2005) as reported by the Oncomine microarray database. The
levels of BRG1 mRNA in the indicated number (N) of malignant
melanoma samples were determined to be significantly higher than
those in samples from normal skin (p = 2.9 × 10
-7).
Additional File 2: Extracellular Matrix and Adhesion molecule RT
2
Profiler PCR Array. The expression of 84 extracellular and adhesion
molecule related genes was profiled in control SK-MEL5 (empty vector)
and BRG1 reconstituted SK-MEL5 cells using a focused qPCR array. For
each primer set, the fold change in SK-MEL5+BRG1 cells was determined
relative to values obtained in control SK-MEL5 cells +empty vector.
Statistical significance was calculated using the student’s t test (*
indicates p < 0.05, **indicates p < 0.01). All other values were found to
be not significantly different. Expression of genes that were activated by
BRG1 greater than 2 fold are highlighted in red. Expression of genes that
were down-regulated by BRG1 at least 2 fold are highlighted in green. N.
D. represents genes that were not detected by the qRT-PCR assay or that
had CT values > 34.
Additional File 3: Cell Confluency and SWI/SNF Subunit Expression.
Western blot showing the effect of increasing confluency on the
expression of BRG1, BRM, and INI1 in WM2664 cells that were cultured in
the absence of serum. Tubulin is a loading control.
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